Despite significant progress achieved
in artificial self-sorting
in solution, operating self-sorting in the body remains a considerable
challenge. Here, we report an in vivo self-sorting peptide system
via an in situ assembly evolution for combined cancer therapy. The
peptide E3C16-SS-EIY consists of two disulfide-connected
segments, E3C16SH and SHEIY, capable of
independent assembly into twisted or flat nanoribbons. While E3C16-SS-EIY assembles into nanorods, exposure to glutathione
(GSH) leads to the conversion of the peptide into E3C16SH and SHEIY, thus promoting in situ evolution from the
nanorods into self-sorted nanoribbons. Furthermore, incorporation
of two ligand moieties targeting antiapoptotic protein XIAP and organellar
endoplasmic reticulum (ER) into the self-sorted nanoribbons allows
for simultaneous inhibition of XIAP and accumulation surrounding ER.
This leads to the cytotoxicity toward the cancer cells with elevated
GSH levels, through activating caspase-dependent apoptosis and inducing
ER dysfunction. In vivo self-sorting of E3C16-SS-EIY decorated
with ligand moieties is thoroughly validated by tissue studies. Tumor-bearing
mouse experiments confirm the therapeutic efficacy of the self-sorted
assemblies for inhibiting tumor growth, with excellent biosafety.
Our findings demonstrate an efficient approach to develop in vivo
self-sorting systems and thereby facilitating in situ formulation
of biomedical agents.